Association between - 174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population

DNA and Cell Biology

Volumn 27, Issue 9, 2008, Pages 505-510

  Kesarwani, Pravin ^a   Ahirwar, Dinesh Kumar ^a   Mandhani, Anil ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GLEASON SCORE; HUMAN; INDIAN; INTRON; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TOBACCO; VARIABLE NUMBER OF TANDEM REPEAT;

AGED; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; INTERLEUKIN-4; INTERLEUKIN-6; MALE; MIDDLE AGED; MINISATELLITE REPEATS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; SMOKING;

NICOTIANA TABACUM;

EID: 50849126032     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2008.0742     Document Type: Article

References (29)

1. Bidwell, J., Keen, L., Gallagher, G., Kimberly, R., Huizinga, T., McDermott, M.F., Oksenberg, J., McNicholl, J., Pociot, F., Hardt, C., and D'Alfonso, S. (2001). Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2, 61-70.
2. Cabrespine, A., Bay, J.O., Verrelle, P., and Morel, L. (2007). Interleukin-6 implication in prostate cancer. Bull Cancer 94, F29-F34.
3. Chen, H., Cowan, M.J., Hasday, J.D., Vogel, S.N., and Medvedev, A.E. (2007). Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 179, 6097-6106.
4. Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867.
5. Dancescu, M., Rubio-Trujillo, M., Biron, G., Bron, D., Delespesse, G., and Sarfati, M. (1992). Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176, 1319-1326.
6. Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J.S., Humphries, S., and Woo, P. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102, 1369-1376.
7. Gleason, D.F., and the V.A.C.U.R.G. (1997). Histological grading and clinical staging of prostatic carcinoma. In Urologic Pathology. Tannenbaum, M. ed. (Lea & Febiger, Inc., Philadelphia, PA), pp. 171-197.
8. Hegab, A.E., Sakamoto, T., Saitoh, W., Massoud, H.H., Massoud, H.M., Hassanein, K.M., and Sekizawa, K. (2004). Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 126, 1832-1839.
9. Hobisch, A., Ramoner, R., Fuchs, D., Godoy-Tundidor, S., Bartsch, G., Klocker, H., and Culig, Z. (2001). Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7, 2941-2948.
10. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., and Thun, M.J. (2005). Cancer statistics, 2005. CA Cancer J Clin 55, 10-30.
11. Kamimura, D.O., Ishihara, K.O., and Hirano, T.O. (2003). IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149, 1-38.
12. Lee, S.O., Chun, J.Y., Nadiminty, N., Lou, W., and Gao, A.C. (2007). Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67, 764-773.
13. Lee, S.O., Lou, W., Hou, M., deMiguel, F., Gerber, L., and Gao, A.C. (2003). Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9, 370-376.
14. Lee, S.O., Pinder, E., Chun, J.Y., Lou, W., Sun, M., and Gao, A.C. (2008). Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 68, 85-91.
15. McCarron, S.L., Edwards, S., Evans, P.R., Gibbs, R., Dearnaley, D.P., Dowe, A., Southgate, C., Easton, D.F., Eeles, R.A., and Howell, W.M. (2002). Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62, 3369-3372.
16. Michaud, D.S., Daugherty, S.E., Berndt, S.I., Platz, E.A., Yeager, M., Crawford, E.D., Hsing, A., Huang, W.Y., and Hayes, R.B. (2006). Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66, 4525-4530.
17. Miller, S.A., Dykes, D.D., and Polesky, H.F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215.
18. Mishra, D., Thangaraj, K., Mandhani, A., Kumar, A., and Mittal, R. (2005). Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population? Clin Genet 68, 55-60.
19. Mout, R., Willemze, R., and Landegent, J.E. (1991). Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res 19, 3763.
20. Paule, B., Terry, S., Kheuang, L., Soyeux, P., Vacherot, F., and de la Taille, A. (2007). The NF-κB/IL-6 pathway in metastatic static androgen-independent prostate cancer: new therapeutic approaches? World J Urol 25, 477-489.
21. Puri, R.K., Leland, P., Obiri, N.I., Husain, S.R., Mule, J., Pastan, I., and Kreitman, R.J. (1996). An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Cell Immunol 171, 80-86.
22. Quinn, M., and Babb, P. (2002). Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90, 162-173.
23. Shariat, S.F., Andrews, B., Kattan, M.W., Kim, J., Wheeler, T.M., and Slawin, K.M. (2001). Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58, 1008-1015.
24. Srivastava, D.S., Mandhani, A., Mittal, B., and Mittal, R.D. (2005). Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int 95, 170-173.
25. Sun, J., Hedelin, M., Zheng, S.L., Adami, H.O., Bensen, J., Augustsson-Bälter, K., Chang, B., Adolfsson, J., Adams, T., Turner, A., Meyers, D.A., Isaacs, W.B., Xu, J., and Grönberg, H. (2004). Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 13, 1677-1679.
26. Takeshi, U., Sadar, M.D., Suzuki, H., Akakura, K., Sakamoto, S., Shimbo, M., Suyama, T., Imamoto, T., Komiya, A., Yukio, N., and Ichikawa, T. (2005). Interleukin-4 in patients with prostate cancer. Anticancer Res 25, 4595-4598.
27. Tan, D., Wu, X., Hou, M., Lee, S.O., Lou, W., Wang, J., Janarthan, B., Nallapareddy, S., Trump, D.L., and Gao, A.C. (2005). Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174, 753-756.
28. Ueda, T., Bruchovsky, N., and Sadar, M.D. (2002). Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277, 7076-7085.
29. Wegiel, B., Bjartell, A., Culig, Z., and Persson, J.L. (2008). Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 122, 1521-1529.